StockUS listing USMKGAFPINKHealthcareDeep Value

MERCK Kommanditgesellschaft auf Aktien(MKGAF) Stock Analysis | Healthcare

USD --+0.00%
Reward44Moderate
Risk32Moderate
75%Data
USD —+0.00 (+0.00%) Previous close · PINK
Market cap 63.38Bn
Reward Ratingⓘ44 Moderate reward assessment · 75% data coverage
Bottom 25% of stocksView factors
Risk Ratingⓘ32 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on MKGAF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is MERCK Kommanditgesellschaft auf Aktien?

Merck KGaA operates as a science and technology company in Germany and internationally.

AI Brief Pro

The brief on MERCK Kommanditgesellschaft auf Aktien

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is MERCK Kommanditgesellschaft auf Aktien?

Merck KGaA operates as a science and technology company in Germany and internationally. It operates through Life Science, Healthcare, and Electronics segments. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 63.38B, and a P/E ratio of 18.2x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Adequate profitability with some margin variability in recent periods.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (44)

Similar stocks to compare

A short list of Drug Manufacturers - Specialty & Generic names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
P/E Ratio18.1768
Beta0.73
Insider Activity
12M windowNo data
No insider activity data available for this ticker.